Literature DB >> 27574388

Early Amiodarone-Induced Pulmonary Toxicity after Endovascular Aneurysm Repair: A Case Report.

Uzung Yoon1, Laura Marinelli1, Sayed Ali2, Seymour Huberfeld2, Rafael Barrera1, John B Chang1.   

Abstract

Amiodarone is an antiarrhythmic drug that has been commonly used to treat supraventricular and ventricular arrhythmias. This drug is an iodine-containing compound that tends to accumulate in several organs, including the lungs. Especially, its main metabolically active metabolite desethylamiodarone can adversely affect many organs. A very well-known severe complication of amiodarone therapy is the amiodarone-induced pulmonary toxicity. This article presents the case study of an 82-year-old male patient with acute amiodarone-induced pulmonary toxicity. The patient underwent endovascular aneurysm repair for rapidly increasing abdominal aortic aneurysm. During the postoperative period the patient developed rapid atrial fibrillation and amiodarone therapy was initiated. Subsequently, the patient went into acute respiratory failure and was requiring high supplemental oxygen support and a chest X-ray revealed bilateral pulmonary infiltrates. During the hospital course the patient required mechanical ventilator support. With discontinuation of amiodarone, supportive therapy and steroid treatment patient symptoms significantly improved. Amiodarone-induced pulmonary toxicity must be considered in the differential diagnosis of all patients on the medication with progressive or acute respiratory symptoms. Early discontinuation of amiodarone and aggressive corticosteroid therapy should be considered as a viable treatment strategy.

Entities:  

Keywords:  amiodarone; aneurysm; endovascular; pulmonary toxicity

Year:  2014        PMID: 27574388      PMCID: PMC5001870          DOI: 10.1055/s-0034-1387170

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  20 in total

1.  Postoperative acute respiratory distress syndrome. A complication of amiodarone associated with 100 percent oxygen ventilation.

Authors:  M Saussine; P Colson; M Alauzen; H Mary
Journal:  Chest       Date:  1992-09       Impact factor: 9.410

2.  Ultra-short course of low-dose amiodarone-induced post-operative fatal pulmonary toxicity.

Authors:  Darsana Viswam; Suresh G Nair; Varun Patel
Journal:  J Assoc Physicians India       Date:  2011-07

3.  Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity.

Authors:  J Mankikian; O Favelle; A Guillon; L Guilleminault; B Cormier; A P Jonville-Béra; D Perrotin; P Diot; S Marchand-Adam
Journal:  Respir Med       Date:  2014-02-10       Impact factor: 3.415

4.  Pulmonary fibrosis and amiodarone.

Authors:  J Morera; R Vidal; F Morell; J Ruiz; L L Bernadó; J R Laporte
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-25

5.  Is amiodarone an underrecognized cause of acute respiratory failure in the ICU?

Authors:  H Ashrafian; P Davey
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

6.  A practical guide for clinicians who treat patients with amiodarone: 2007.

Authors:  Nora Goldschlager; Andrew E Epstein; Gerald V Naccarelli; Brian Olshansky; Bramah Singh; Harold R Collard; Elizabeth Murphy
Journal:  Heart Rhythm       Date:  2007-07-20       Impact factor: 6.343

Review 7.  Prescribing amiodarone: an evidence-based review of clinical indications.

Authors:  Patricia Vassallo; Richard G Trohman
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

Review 8.  Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I).

Authors:  W J Martin; E C Rosenow
Journal:  Chest       Date:  1988-05       Impact factor: 9.410

9.  Amiodarone-induced pulmonary toxicity.

Authors:  Desak Ketut Ernawati; Leanne Stafford; Jeffery David Hughes
Journal:  Br J Clin Pharmacol       Date:  2008-05-06       Impact factor: 4.335

10.  Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration.

Authors:  T A Plomp; W M Wiersinga; J M Van Rossum; R A Maes
Journal:  In Vivo       Date:  1987 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.